The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Novel treatment paradigms for AML at ASH 2021
Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, discusses highlights during the symposium on the topic of evidence-based guidance on current paradigms and new therapeutic approaches in acute myeloid leukemia (AML). He emphasizes how much progress has been recently made within the treatment landscape, as well as the development of targeted therapies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
